Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum

References

• Xu A, Balgobind A, Strunk A, et al. Prevalence estimates for pyoderma gangrenosum in the United States: an age- and sex-adjusted population analysis. J Am Acad Dermatol. 2019 Aug 7;pii. S0190-9622(19)32494-6.
   Web of Science ®Google Scholar
• Foessleitner P, Just U, Kiss H, et al. Challenge of diagnosing pyoderma gangrenosum after caesarean section. BMJ Case Rep. 2019 Jul 27;12(7).
   Google Scholar
• Kleinfelder RE, Hin N, Cubelli S, et al. Multiple facial lesions of recalcitrant pyoderma gangrenosum successfully treated with Adalimumab. J Clin Aesthet Dermatol. 2019 May;12(5):28–32.
   PubMedGoogle Scholar
• DaCunha M, Siscos S, Downing M, et al. Pyoderma gangrenosum controlled with rituximab. JAAD Case Rep. 2019 Jun 26;5(7):593–595.
   PubMedGoogle Scholar
• Osaka A, Ide H, Ban S, et al. Pyoderma gangrenosum after radical prostatectomy: case report. Int Cancer Conf J. 2018;7:114–116.
   PubMed Web of Science ®Google Scholar
• Lemos AC, Aveiro D, Santos N, et al. Pyoderma gangrenosum: an uncommon case report and review of the literature. Wounds. 2017;29:61–69.
   Google Scholar
• Weenig RH, Davis MD, Dahl PR, et al. Skin ulcers misdiagnosed a pyoderma gangrenosum. N Engl J Med. 2002;347:1412–1418.
   PubMed Web of Science ®Google Scholar
• Perry HO, Winkelmann RK. Bullous pyoderma gangrenosum and leukemia. Arch Dermatol. 1972;106:901–905.
   PubMed Web of Science ®Google Scholar
• Platzer KD, Kostner L, Vujic I, et al. Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation. J Eur Acad Dermatol Venereol. 2019 Jul 16. DOI:10.1111/jdv.15803.
   PubMed Web of Science ®Google Scholar
• Bromeo AJ, Suller A. Pyoderma gangrenosum of the upper eyelid. BMJ Case Rep. 2019 8;12(7):Jul.
   Google Scholar
• Gupta AS, Ortega-Loayza AG. Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. Ann Hematol. 2019 Sep;98(9):2247–2248.
   PubMed Web of Science ®Google Scholar
• Jain AG, Sharbatji M, Afzal A, et al. Pyoderma gangrenosum in the absence of any underlying predisposing condition: a diagnostic dilemma. Cureus. 2019 Mar 9;11(3):e4213.
   PubMed Web of Science ®Google Scholar
• George C, Deroide F, Rustin M. Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med (Lond). 2019 May;19(3):224–228.
   PubMed Web of Science ®Google Scholar
• Munoz MA, Babu BA. Pyoderma gangrenosum mistaken for diabetic ulcer. Cleve Clin J Med. 2019 May;86(5):319–320.
   PubMed Web of Science ®Google Scholar
• Borda LJ, Wong LL, Marzano AV, et al. Extracutaneous involvement of pyoderma gangrenosum. Arch Dermatol Res. 2019 Aug;311(6):425–434.
   PubMed Web of Science ®Google Scholar
• Cirotteau P, Heron-Mermin D, Dimicoli-Salazar S, et al. Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two? J Eur Acad Dermatol Venereol. 2019 Aug;33(8):e305–e306.
   PubMed Web of Science ®Google Scholar
• Kandula P, Shah KM, Wolverton JE, et al. Pyoderma gangrenosum: a presenting sign of myelodysplastic syndrome in undiagnosed Fanconi anemia. Dermatol Online J. 2019 Jan 15;25(1):1–4.
   PubMedGoogle Scholar
• Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum. A Delphi consensus of international experts. JAMA Dermatol. 2018;154:461–466.
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958.
   PubMed Web of Science ®Google Scholar
• Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55:505–509.
   PubMed Web of Science ®Google Scholar
• Rizzuto A, Gallo G, Trompetto M, et al. Pyoderma gangrenosum as first manifestation of Crohn’s disease. Tech Coloproctol. 2019 Jan;23(1):79–80.
   PubMed Web of Science ®Google Scholar
• Maverakis E, Le ST, Callen J, et al. New validated diagnostic criteria for pyoderma gangrenosum. J Am Acad Dermatol. 2019 Apr;80(4):e87–e88.
   PubMed Web of Science ®Google Scholar
• Ashchyan HJ, Butler DC, Nelson CA, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2019;154(4):409–413.
   Google Scholar
• SF B, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum(PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–698.
   PubMed Web of Science ®Google Scholar
• Jockenhöfer F, Wollina U, Salva KA, et al. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol. 2019 Mar;180(3):615–620.
   PubMed Web of Science ®Google Scholar
• Miller J, Yentzer BA, Clark A, et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646–654.
   PubMed Web of Science ®Google Scholar
• Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018 Mar;14(3):225–233.
   PubMed Web of Science ®Google Scholar
• Wenzel J, Gerdsen R, Phillipp–Dormston W, et al. Topical treatment of pyoderma gangraenosum. Dermatology. 2002;205:221–223.
   PubMed Web of Science ®Google Scholar
• Caughman W, Stern R, Haynes H. Neutrophilic dermatosis of myeloproliferative disorders. J Am Acad Dermatol. 1983;9:751–758.
   PubMed Web of Science ®Google Scholar
• HH S, MM M, CW S, et al. Culture and immunohistochemical evidence of chlamydia infection in ulcerative pyoderma gangrenosum. J Am Acad Dermatol. 2003;48:966–969.
   PubMed Web of Science ®Google Scholar
• Dillingham CS, Jorizzo J. Managing ulcers associated with pyoderma gangrenosum with a urinary bladder matrix and negative-pressure wound therapy. Adv Skin Wound Care. 2019 Feb;32(2):70–76.
   PubMed Web of Science ®Google Scholar
• Talansky AL, Meyers S, Greenstein AJ, et al. Does intestinal resection heal pyoderma gangrenosum of inflammatory bowel disease? J Clin Gastroenterol. 1983;5:207–210.
   PubMed Web of Science ®Google Scholar
• Abdul-Fattah B, Al-Muriesh M, Huang CZ. Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum. Dermatol Ther. 2018 Sep;31(5):e12697.
   PubMed Web of Science ®Google Scholar
• Powell FC, O’Kane M. Management of pyoderma gangrenosum. Dermatol Clin. 2002;20:347–355.
   PubMed Web of Science ®Google Scholar
• Callen JP. Pyoderma gangrenosum. Lancet. 1998;351:581–585.
   PubMed Web of Science ®Google Scholar
• Dissemond J, Erfurt-Berge C, Goerge T, et al. Systemic therapies for leg ulcers. J Dtsch Dermatol Ges. 2018 Jul;16(7):873–890.
   Web of Science ®Google Scholar
• Din RS, Tsiaras WG, Li DG, et al. Efficacy of systemic dapsone treatment for pyoderma gangrenosum: a retrospective review. J Drugs Dermatol. 2018 Oct 1;17(10):1058–1060.
   PubMed Web of Science ®Google Scholar
• Soto Vilches F, Vera-Kellet C. Pyoderma gangrenosum: classic and emerging therapies. Med Clin (Barc). 2017 Sep 20;149(6):256–260.
   PubMed Web of Science ®Google Scholar
• Haag CK, Ortega-loayza AG, Latour E, et al. Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. J Dermatolog Treat. 2019; 1–4.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. 2008.
   Google Scholar
• Song HD, Lahood N, Mostaghimi AD. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum : systematic review of cases and case series *. 2018;363–368. DOI:10.1111/bjd.15850.
   Google Scholar
• Brooklyn T, Dunnill M, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. 2006; 505–509. DOI:10.1136/gut.2005.074815
   Google Scholar
• Mckenzie F, Cash D, Gupta A, et al. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat. 2019;30(3):264–276.
   PubMed Web of Science ®Google Scholar
• Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152(5):1059–1061.
   PubMed Web of Science ®Google Scholar
• Cinotti E, Labeille B, Perrot JL, et al. Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis. Clin Exp Dermatol. 2014;39(6):750–751.
   PubMed Web of Science ®Google Scholar
• Hurabielle C, Schneider P, Baudry C, et al. Certolizumab pegol - A new therapeutic option for refractory disseminated pyoderma gangrenosum associated with Crohn’s disease. J Dermatolog Treat. 2016;27(1):67–69.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Botto NC, Gottlieb AB. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67(5):e237–8.
   PubMed Web of Science ®Google Scholar
• Skalkou A, Manoli SM, Sachinidis A, et al. Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab. Rheumatol Int. 2018;38(1):161–167.
   PubMed Web of Science ®Google Scholar
• Geusau A, Mothes-Luksch N, Nahavandi H, et al. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol. 2013;149(2):209–215.
   PubMed Web of Science ®Google Scholar
• Jaeger T, Andres C, Grosber M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa–rapid response to canakinumab (anti-IL-1beta). Eur J Dermatol. 2013;23(3):408–410.
   PubMed Web of Science ®Google Scholar
• Sun NZ, Ro T, Jolly P, et al. Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa. J Clin Aesthet Dermatol. 2017;10(9):36–38.
   PubMedGoogle Scholar
• Huang W, Nath R, Zayed H, et al. Results of an open-label, proof of concept study of gevokizumab in the treatment of the acute, inflammatory phase of pyoderma gangrenosum. 2014.
   Google Scholar
• XOMA Corporation. XOMA initiates pivotal phase 3 gevokizumab study in patients with pyoderma gangrenosum. 2014.
   Google Scholar
• Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017;31(2):e75–e77.
   PubMed Web of Science ®Google Scholar
• Fleisher M, Marsal J, Lee SD, et al. Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease. Dig Dis Sci. 2018;63(4):825–833.
   PubMed Web of Science ®Google Scholar
• Yeh JE, Tsiaras WG. Intractable pyoderma gangrenosum in a Crohn’s disease patient on vedolizumab. JAAD Case Rep. 2017 Mar 9;3(2):110–112.
   PubMedGoogle Scholar
• Lorincz M, Kleszky M, Szaloki T Jr, et al. Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis. Orv Hetil. 2010;151(4):144–147.
   PubMedGoogle Scholar
• Kochar B, Herfarth N, Mamie C, et al. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019 Apr;17(5):991–993.
   PubMed Web of Science ®Google Scholar
• Shanmugam VK, McNish S, Shara N, et al. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi((R))). J Foot Ankle Surg. 2013;52(6):781–785.
   PubMed Web of Science ®Google Scholar
• Nasifoglu S, Heinrich B, Welzel J. Successful therapy of Pyoderma gangrenosum with a JAK2 inhibitor. Br J Dermatol. 2018 Aug;179(2):504–505.
   PubMed Web of Science ®Google Scholar
• Laird ME, Tong LX, Lo Sicco KI, et al. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2017;3(3):228–229.
   PubMedGoogle Scholar